A randomised controlled trial of dexmedetomidine for delirium in adults undergoing heart valve surgery

作者：Hongxing Wang, Yuan Jia, Congya Zhang, L. Zhang, Yu-Xian Li, Jian Ding, Xinhai Wu, Zheng Zhang, Jingsheng Wang, Yuyan Wang, Fuxia Yan, Su Yuan, Daniel I. Sessler · 发表于：Anaesthesia · 年份：2023 · DOI：10.1111/anae.15983 · 被引用次数：32 · 研究领域：Intensive Care Unit Cognitive Disorders、Anesthesia and Sedative Agents、Anesthesia and Neurotoxicity Research

Summary Dexmedetomidine might reduce delirium after cardiac surgery. We allocated 326 participants to an infusion of dexmedetomidine at a rate of 0.6 μg kg −1 for 10 min and then at 0.4 μg.kg −1 .h −1 until the end of surgery; 326 control participants received comparable volumes of saline. We detected delirium in 98/652 (15%) participants during the first seven postoperative days: 47/326 after dexmedetomidine vs. 51/326 after placebo, p = 0.62, adjusted relative risk (95%CI) 0.86 (0.56–1.33), p = 0.51. Postoperative renal impairment (Kidney Disease Improving Global Outcomes stages 1, 2 and 3) was detected in 46, 9 and 2 participants after dexmedetomidine and 25, 7 and 4 control participants, p = 0.040. Intra‐operative dexmedetomidine infusion did not reduce the incidence of delirium after cardiac valve surgery but might impair renal function.